Plasma Chemokine CCL2 and Its Receptor CCR2 Concentrations as Diagnostic Biomarkers for Breast Cancer Patients

Table 3

Diagnostic criteria of tested parameters and in combined analysis with CA 15-3 in breast cancer patients.

Tested parameters	Diagnostic criteria ()	Breast cancer
		Stage I	Stage II	Stage III/IV	Total group
CCL2	SE	58.82	58.54	86.36	64.95
	SP	73.02	73.02	73.02	73.02
	PPV	54.05	58.54	52.78	78.75
	NPV	76.67	73.02	93.88	57.50
CCR2	SE	55.88	58.50	77.27	61.86
	SP	73.02	73.02	73.02	73.02
	PPV	52.78	58.54	50.00	77.92
	NPV	75.41	73.02	90.20	55.42
CA 15-3	SE	50.00	53.66	86.36	59.79
	SP	85.71	85.71	85.71	85.71
	PPV	65.38	70.97	67.86	86.57
	NPV	76.06	73.97	94.74	58.06
CCL2+ CA 15-3	SE	73.53	70.73	95.45	77.32
	SP	63.49	63.49	63.49	63.49
	PPV	52.08	55.77	47.73	76.53
	NPV	81.63	76.92	97.56	64.52
CCR2+ CA 15-3	SE	70.59	82.93	86.36	79.38
	SP	65.08	65.08	65.08	65.08
	PPV	52.17	60.71	46.34	77.78
	NPV	80.39	85.42	93.18	67.21
CCL2+CCR2+ CA 15-3	SE	85.29	92.68	95.45	90.72
	SP	44.44	44.44	44.44	44.44
	PPV	45.31	52.05	37.50	71.54
	NPV	84.85	90.32	96.55	75.68